Literature DB >> 33496893

Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis.

Raseen Tariq1,2, Maham Hayat3, Darrell Pardi1, Sahil Khanna4.   

Abstract

Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridioides difficile infection (CDI), with ~15% 1-year recurrence rate. Small studies have identified variable risk factors associated with FMT failure. We, therefore, performed a systematic review and meta-analysis to evaluate the predictors of FMT failure. A systematic search of Medline, Embase, and Web of Science was performed from January 2013 up to June 2020. Meta-analyses were performed using random-effects models and pooled adjusted odds ratios for risk factors reported in ≥2 studies were calculated. Overall, 2671 patients with recurrent CDI who underwent FMT in 12 studies were included. FMT failure occurred in 454 patients (16.9%) with median follow-up of 3 months (range 2-7.7 months). A total of 9 risk factors were identified in ≥2 studies. Meta-analysis showed that use of non- CDI antibiotics, presence of inflammatory bowel disease, poor quality of bowel preparation, CDI-related hospitalization before FMT, inpatient FMT, and severe CDI were associated with statistically significant increased risk of failure after FMT. Increasing age, female gender, and immunocompromised status were not associated with increased risk for FMT failure. Several risk factors (both modifiable and non-modifiable) are associated with FMT failure. Lower use of antibiotics in the post-FMT period and good bowel preparation at the time of FMT are associated with lower risk of failure after FMT. Additionally, patients with non-modifiable risk factors should be counseled to be particularly alert about recurrent symptoms after FMT.

Entities:  

Keywords:  C. difficile; Failure; Fecal microbiota transplantation

Year:  2021        PMID: 33496893     DOI: 10.1007/s10096-021-04163-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.

Authors:  Alexander Khoruts; Kevin M Rank; Krista M Newman; Kimberly Viskocil; Byron P Vaughn; Matthew J Hamilton; Michael J Sadowsky
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

2.  Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Monika Fischer; Dina Kao; Colleen Kelly; Aishwarya Kuchipudi; Syed-Mohammed Jafri; Mark Blumenkehl; Douglas Rex; Mark Mellow; Nirmal Kaur; Harry Sokol; Gwen Cook; Matthew J Hamilton; Emmalee Phelps; Brian Sipe; Huiping Xu; Jessica R Allegretti
Journal:  Inflamm Bowel Dis       Date:  2016-10       Impact factor: 5.325

3.  Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure.

Authors:  Jessica R Allegretti; Dina Kao; Jessica Sitko; Monika Fischer; Zain Kassam
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study.

Authors:  Monika Fischer; Dina Kao; Shama R Mehta; Tracey Martin; Joseph Dimitry; Ammar H Keshteli; Gwendolyn K Cook; Emmalee Phelps; Brian W Sipe; Huiping Xu; Colleen R Kelly
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

6.  Predictors of fecal transplant failure.

Authors:  Alireza Meighani; Benjamin R Hart; Chetan Mittal; Nichole Miller; Ajin John; Mayur Ramesh
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-07       Impact factor: 2.566

7.  Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea.

Authors:  Alexander Khoruts; Johan Dicksved; Janet K Jansson; Michael J Sadowsky
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

Review 8.  Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection.

Authors:  Y-T Li; H-F Cai; Z-H Wang; J Xu; J-Y Fang
Journal:  Aliment Pharmacol Ther       Date:  2015-12-14       Impact factor: 8.171

Review 9.  Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.

Authors:  M N Quraishi; M Widlak; N Bhala; D Moore; M Price; N Sharma; T H Iqbal
Journal:  Aliment Pharmacol Ther       Date:  2017-07-14       Impact factor: 8.171

Review 10.  Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives.

Authors:  Hyun Ho Choi; Young-Seok Cho
Journal:  Clin Endosc       Date:  2016-03-09
View more
  5 in total

1.  Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.

Authors:  Maribeth R Nicholson; Erin Alexander; Sonia Ballal; Zev Davidovics; Michael Docktor; Michael Dole; Jonathan M Gisser; Alka Goyal; Suchitra K Hourigan; M Kyle Jensen; Jess L Kaplan; Richard Kellermayer; Judith R Kelsen; Melissa A Kennedy; Sahil Khanna; Elizabeth D Knackstedt; Jennifer Lentine; Jeffery D Lewis; Sonia Michail; Paul D Mitchell; Maria Oliva-Hemker; Tiffany Patton; Karen Queliza; Sarah Sidhu; Aliza B Solomon; David L Suskind; Madison Weatherly; Steven Werlin; Edwin F de Zoeten; Stacy A Kahn
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

Review 2.  Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Authors:  Rachel Bernard; Suchitra K Hourigan; Maribeth R Nicholson
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

Review 3.  Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.

Authors:  Tae-Geun Gweon; Yoo Jin Lee; Kyeong Ok Kim; Sung Kyun Yim; Jae Seung Soh; Seung Young Kim; Jae Jun Park; Seung Yong Shin; Tae Hee Lee; Chang Hwan Choi; Young-Seok Cho; Dongeun Yong; Jin-Won Chung; Kwang Jae Lee; Oh Young Lee; Myung-Gyu Choi; Miyoung Choi
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

Review 4.  The emerging potential of microbiome transplantation on human health interventions.

Authors:  Howard Junca; Dietmar H Pieper; Eva Medina
Journal:  Comput Struct Biotechnol J       Date:  2022-01-19       Impact factor: 7.271

5.  Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?

Authors:  Daniel Popa; Bogdan Neamtu; Manuela Mihalache; Adrian Boicean; Adela Banciu; Daniel Dumitru Banciu; Doru Florian Cornel Moga; Victoria Birlutiu
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.